Basal cell carcinoma (BCC) is the single most common cancer in humans. In the United States alone, it accounts for a large share of the roughly 5.4 million non-melanoma skin cancers diagnosed each year, and the lifetime risk for white populations in North America has reached an estimated 30%. Nearly 1 in 5 Americans will develop some form of BCC over the course of their life.
BCC by the Numbers
BCC outnumbers every other type of skin cancer. Across all age groups, BCC is treated about 1.7 times more often than squamous cell carcinoma, the second most common skin cancer. That gap is even wider in younger adults: among people aged 18 to 39, BCC is nearly 10 times more common than squamous cell carcinoma. By age 65 and older, the ratio narrows to roughly 1.3 to 1, because squamous cell carcinoma becomes increasingly common with age as well.
Compared to melanoma, BCC is far more frequent but far less dangerous. The five-year survival rate for BCC is close to 100%, because these tumors grow slowly and almost never spread to other organs. Cancer registries don’t even track BCC survival statistics the way they do for melanoma, precisely because fatal outcomes are so rare. That said, BCC can cause significant local tissue damage if it’s ignored, particularly on the face, ears, and nose.
Who Gets It Most Often
Age is the biggest predictor. BCC accumulates over a lifetime of sun exposure, so rates climb steadily with each decade. But the pattern differs between men and women in an interesting way. Women under 40 actually develop BCC at higher rates than men of the same age, likely due in part to indoor tanning. After age 50, men pull ahead, and by ages 60 to 80, male rates are significantly higher. Over a full lifetime, the rate of increase in BCC risk is roughly 20% faster in men than in women.
Skin color matters, though not as absolutely as many people assume. BCC is most common in people with fair skin, light eyes, and a tendency to burn rather than tan. But it occurs in every skin tone. Data from Singapore showed that elderly Chinese individuals with moderate skin tones developed non-melanoma skin cancer at three times the rate of Malays and Indians with darker skin. Among all racial groups in the U.S., BCC is more common than squamous cell carcinoma: the ratio holds for white, Hispanic, Asian, and Black patients alike. One concern is that people with darker skin often receive a delayed diagnosis, leading to larger tumors and worse outcomes despite the lower overall frequency.
Where in the World BCC Is Most Common
Geography plays a major role. High-income North America has the highest BCC incidence on Earth, followed by Western Europe. In the population aged 55 and older, the U.S. had an age-standardized incidence rate of roughly 2,556 per 100,000 people in 2021, more than nine times higher than the next-highest countries, Sweden and Greenland. At the other end of the spectrum, countries like Nepal, Bangladesh, and Bhutan report rates near 0.03 per 100,000.
The pattern tracks closely with two factors: latitude (and therefore UV intensity) and the skin pigmentation of the predominant population. Countries closer to the equator but with darker-skinned populations have low rates, while countries with fair-skinned populations and strong outdoor cultures have high ones. Australia, though not broken out in the data above, is historically one of the highest-incidence countries for the same reasons.
Rates Are Still Climbing
BCC has been increasing steadily for decades, and there’s no sign of a plateau. Globally, BCC incidence rose by 77% between 1990 and 2017. The annual rate of increase is about 1.8%, which is actually faster than the rise in melanoma (about 0.7% per year). In white North American populations, incidence has grown by more than 10% per year in some periods.
Several forces are driving this trend. People are living longer, which means more cumulative UV exposure. Outdoor recreation remains popular. Ozone layer thinning in certain regions has increased ground-level UV radiation. And greater awareness has led to more screening and more diagnoses, which inflates the apparent rate even if the true biological rate were stable. Still, most researchers agree the increase is real and not just a detection artifact.
What Happens After a First Diagnosis
If you’ve been diagnosed with one BCC, you’re at elevated risk of developing another. The recurrence rate after surgical removal depends on the technique used and the type of tumor. For Mohs surgery, which is the most precise option typically reserved for facial or aggressive tumors, the five-year recurrence rate is about 2.1% for tumors being treated for the first time and 5.2% for tumors that had already recurred after a previous treatment.
Beyond the same spot recurring, people who’ve had one BCC have a substantially higher chance of developing an entirely new BCC somewhere else on their body in the following years. This is because the underlying risk factors, cumulative sun damage and skin type, affect the whole body, not just one spot. Regular skin checks after a first diagnosis are standard practice for this reason.
Putting the Risk in Perspective
BCC is extremely common but rarely life-threatening. It’s the kind of cancer where the word “cancer” can be more alarming than the condition itself. Most BCCs are caught early, removed in a straightforward office procedure, and never cause further problems. The real cost is in volume: millions of procedures each year, ongoing surveillance, and the cumulative toll of repeated surgeries for people who develop multiple lesions over time. For any individual, the prognosis is excellent. For health systems, the sheer scale of BCC makes it one of the most resource-intensive cancers to manage.